Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CFTR | P13569 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895994 | 0.86 | ALDH1A1 (0.67) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL18225469 | 0.83 | ABL1 (0.51) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL1340852 | 0.81 | CES2 (0.61) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL505249 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL31589985 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL17707771 | 0.81 | CES2 (0.39) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL17707768 | 0.81 | NPC1 (0.49) | ALDH1A1HSD17B10KMT2ALMNACA1 | |
| SCHEMBL8758926 | 0.81 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KMT2ATSHRLMNA | |
| SCHEMBL513707 | 0.80 | KMT2A (0.67) | ALDH1A1HSD17B10CFTRKMT2ATSHR | |
| SCHEMBL29930913 | 0.80 | KMT2A (0.67) | ALDH1A1HSD17B10CFTRKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0343752-A1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DowElanco (US) | 1989-11-29 | — | — | EP | claimed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-120117999-A | Fluorotranilast derivatives and medical application thereof | 中国药科大学 | 2025-06-10 | — | — | CN | disclosed |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2025-01-09 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2193121-A1 | QUINOLIN-4-ONE AND 4-OXODIHYDROCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009027730-A1 | QUINOLIN-4-ONE AND 4-OXODIHYDROCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-03-05 | — | — | WO | disclosed |
| EP-0537611-B1 | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides | DOW AGROSCIENCES LLC (US) | 1998-08-12 | — | — | EP | disclosed |
| US-5543550-A | NITRATING ALKYL ESTER OF 3-FLUOROBENZOIC ACID DISSOLVED IN SOLVENT-FREE SULFURIC ACID, THEN ADDING WATER, SEPARATION, HYDROLYSIS, PRESSURIZED CATALYTIC HYDROGENATION OF THE NITRATED ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-08-06 | — | — | US | disclosed |
| EP-0537611-A1 | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides | DOWELANCO (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5177206-A | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides | DOWELANCO (US) | 1993-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | BRCA1, TP53, BCCIP | ALDH1A1 729/4885HSD17B10 2085/4885CFTR 3469/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885HSD17B10 847/4885CFTR 341/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885HSD17B10 1426/4885CFTR 1214/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | ALDH1A1 1823/4885HSD17B10 3384/4885CFTR 917/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | ALDH1A1 1201/4885HSD17B10 1234/4885CFTR 2526/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 1136/4885HSD17B10 847/4885CFTR 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.